

**Freedom of Information Act 2000 – Request Reference FoI/23/670**  
**Dermatological Treatment**

**Question 1. How many patients were treated in the last 4 months (August to November 2023) by the dermatology department with each of the following products:**

For the period 1 August 2023 to 30 November 2023:

- Abrocitinib: 1
- Acitretin: 125
- Alitretinoin: 13
- Azathioprine: 1
- Baricitinib: 6
- Ciclosporin: 10
- Dupilumab: 85
- Methotrexate: 14
- Mycophenolate mofetil: 1
- Pimecrolimus: 2
- Phototherapy (UVB or PUVA) – for Atopic Dermatitis only: 42 for UVB and 19 for UVA.
- Tacrolimus ointment: 14
- Tralokinumab: 2
- Upadacitinib: 7

**Question 2. Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group:**

For all the above products, with the exception of Phototherapy, the figures are as follows.

- Age 6–11: 5
- Age 12–17: 11
- Age 18 and above: 256

For phototherapy only, there were 9 patients treated with UVB aged under 16 years, and 4 treated between the ages 16–18. There were 29 patients treated with UVB aged over 18 years. All 19 patients treated with UVA were over 18 years.